Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05, Zacks reports. The business had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.

Heron Therapeutics Stock Performance

Shares of HRTX traded up $0.25 during mid-day trading on Friday, hitting $2.30. 2,143,244 shares of the stock were exchanged, compared to its average volume of 1,630,635. The firm has a 50-day moving average of $1.67 and a two-hundred day moving average of $1.71. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a market cap of $349.82 million, a PE ratio of -12.80 and a beta of 1.60.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 29th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.